Mumbai, July 25 — Pharma major Cipla Ltd. has posted a strong financial performance for the first quarter of FY26, with consolidated net profit rising 10% year-on-year to ₹1,298 crore, up from ₹1,178 crore in Q1FY25. The company’s revenue from operations grew 3.9% to ₹6,957 crore, driven by robust domestic and international sales.
Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) stood at ₹1,778 crore, reflecting a 4% increase YoY, with a stable margin of 25.6%. Profit before tax reached ₹1,770 crore.
Cipla’s India business crossed the ₹3,000 crore mark for the first time in any opening quarter, registering a 6% YoY growth to ₹3,070 crore. The branded prescription segment outpaced market growth, while trade generics and consumer health anchor brands maintained leadership positions.
International performance was mixed:
- North America revenue declined 7% YoY to ₹1,933 crore
- Africa sales rose 14% to ₹871 crore
- Europe and Emerging Markets posted 11% growth to ₹861 crore
R&D investments totaled ₹432 crore, accounting for 6.2% of total sales, with a focus on product filings and pipeline development. Cipla’s net cash position stood at ₹10,379 crore, while total debt was reported at ₹459 crore.
Managing Director and Global CEO Umang Vohra emphasized continued progress across key markets and reaffirmed the company’s commitment to expanding flagship brands and resolving regulatory challenges. Cipla’s shares rose nearly 4% following the earnings announcement.
